Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics

Pharmacogenomics

Volumn 12, Issue 1, 2011, Pages 113-124

  Becquemont, Laurent ^a   Alfirevic, Ana ^b   Amstutz, Ursula ^c,d   Brauch, Hiltrud ^e   Jacqz Aigrain, Evelyne ^f   Laurent Puig, Pierre ^g,h   Molina, Miguel A ⁱ   Niemi, Mikko ^j   Schwab, Matthias ^d   Somogyi, Andrew A ^k   Thervet, Eric ^g,l   Maitland Van Der Zee, Anke Hilse ^m   Van Kuilenburg, André B P ⁿ   Van Schaik, Ron H N ^o   Verstuyft, Céline ^a   Wadelius, Mia ^p   Daly, Ann K ^q  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ INSTITUT UNIVERSITARI DEXEUS   (Spain)

^j UNIVERSITY OF HELSINKI   (Finland)

^k UNIVERSITY OF ADELAIDE   (Australia)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m UTRECHT UNIVERSITY   (Netherlands)

ⁿ ACADEMIC MEDICAL CENTER   (Netherlands)

^o ERASMUS MEDICAL CENTER   (Netherlands)

^p UPPSALA UNIVERSITY   (Sweden)

^q NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

adverse drug reaction; azathioprine; cetuximab; clopidogrel; gefitinib; genetic testing; pharmacogenetics; statins; tacrolimus; tamoxifen; warfarin

Indexed keywords

ABACAVIR; AROMATASE INHIBITOR; ATORVASTATIN; AZATHIOPRINE; B RAF KINASE; CETUXIMAB; CLOPIDOGREL; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUCLOXACILLIN; FLUOROURACIL; GEFITINIB; HLA B ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; K RAS PROTEIN; MERCAPTOPURINE; ORGANIC ANION TRANSPORTER 2; PANITUMUMAB; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROTEIN TYROSINE KINASE INHIBITOR; SIMVASTATIN; TACROLIMUS; TAMOXIFEN; UNINDEXED DRUG; WARFARIN; PRESCRIPTION DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BIOMEDICINE; BLOOD TOXICITY; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; CROHN DISEASE; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; HAND FOOT SYNDROME; HUMAN; LIVER INJURY; LUNG NON SMALL CELL CANCER; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PHARMACOGENOMICS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; SYMPOSIUM; CONFERENCE PAPER; METHODOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE;

HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION DRUGS;

EID: 78650447994     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.147     Document Type: Article

References (47)

1. Rosell R, Moran T, Queralt C et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
2. Maemondo M, Inoue A, Kobayashi K et al.: Geftinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
3. Mok TS, Wu Yl, Thongprasert S et al.: Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
4. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
5. Maheswaran S, Sequist LV, Nagrath S et al.: Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
6. Tsao MS, Sakurada A, Cutz JC et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005).
7. Lievre A, Bachet JB, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
8. Lievre A, Laurent-Puig P: Genetics: predictive value of KRAS mutations in che mo resistant CRC. Nat. Rev. Clin. Oncol. 6(6), 306-307 (2009).
9. Van Cutsem E, Kohne CH, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
10. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-RAS mutations and beneft from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
11. Amado RG, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab effcacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
12. Schroth W, Antoniadou L, Fritz P et al.: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33), 5187-5193 (2007).
13. Schroth W, Goetz MP, Hamann U et al.: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
14. Jin Y, Desta Z, Stearns V et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
15. Bonanni B, Macis D, Maisonneuve P et al.: Polymorphism in the CYP2D6 tamoxifen-metabolizing gene infuences clinical effect but not hot fashes: data from the italian tamoxifen trial. J. Clin. Oncol. 24(22), 3708-3709; author reply 3709 (2006).
16. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang Ij, Ro J: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25(25), 3837-3845 (2007).
17. Dehal SS, Kupfer D: CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57(16), 3402-3406 (1997).
18. Rebsamen MC, Desmeules J, Daali Y et al.: The amplichip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 9(1), 34-41 (2009).
19. Van Kuilenburg AB, Meijer J, Mul AN et al.: Analysis of severely affected patients with dihydropyrimidine dehydrogenase defciency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3). Hum. Genet. 125(5-6), 581-590 (2009).
20. Amstutz U, Farese S, Aebi S, Largiader CR: Dihydropyrimidine dehydrogenase gene variation and severe 5-fuorouracil toxicity: a haplotype assessment. Pharmacogenomics 10(6), 931-944 (2009).
21. Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E: The infuence of fuorouracil outcome parameters on tolerance and effcacy in patients with advanced colorectal cancer. Pharmacogenomics J. 8(4), 256-267 (2008).
22. Morel A, Boisdron-Celle M, Fey L et al.: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fuorouracil tolerance. Mol. Cancer Ther. 5(11), 2895-2904 (2006).
23. Schwab M, Zanger UM, Marx C et al.: Role of genetic and nongenetic factors for fuorouracil treatment-related severe toxicity: a prospective clinical trial by the german 5-FU toxicity study group. J. Clin. Oncol. 26(13), 2131-2138 (2008).
24. Magne N, Etienne-Grimaldi MC, Cals L et al.: Dihydropyrimidine dehydrogenase activity and the IVS14 + 1G
25. Mcleod HL, Sargent DJ, Marsh S et al.: Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial n9741. J. Clin. Oncol. 28(20), 3227-3233 (2010).
26. Boisdron-Celle M, Remaud G, Traore S et al.: 5-fuorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase defciency Cancer Lett. 249(2), 271-282 (2007).
27. Teml A, Schaeffeler E, Schwab M: Pretreatment determination of TPMT - state of the art in clinical practice. Eur. J. Clin. Pharmacol. 65(3), 219-221 (2009).
28. Schwab M, Schaffeler E, Marx C et al.: Azathioprine therapy and adverse drug reactions in patients with infammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12(6), 429-436 (2002).
29. Kaskas BA, Louis E, Hindorf U et al.: Safe treatment of thiopurine S-methyltransferase defcient Crohn's disease patients with azathioprine. Gut 52(1), 140-142 (2003).
30. Wadelius M, Chen L, Lindh J et al.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).
31. Klein TE, Altman RB et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
32. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
33. Schwartz U, Ritchie M, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
34. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (9154), 717-719 (1999).
35. Van Schie RM, Wadelius MI, Kamali F et al.: Genotype-guided dosing of coumarin derivatives: The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
36. Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4), 363-375 (2009).
37. Mega J, Close S, Wiviott S et al.: Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl. J. Med. 360(4), 354-362 (2009).
38. Sibbing D, Stegherr J, Latz W et al.: CYP450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J. 30(8), 916-922 (2009).
39. Mallal S, Phillips E, Carosi G et al.: HlA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
40. Daly A, Donaldson P, Bhatnagar P et al.: HlA-B*5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41, 816-819 (2009).
41. Niemi M: Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87(1), 130-133 (2010).
42. Search Collaborative Group, Link E, Parish S et al.: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
43. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fuvastatin. Clin. Pharmacol. Ther. 80(4), 356-366 (2006).
44. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16(12), 873-879 (2006).
45. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82(6), 726-733 (2007).
46. Thervet E, Loriot MA, Barbier S et al.: Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010).
47. Zhao W, Elie V, Roussey G et al.: Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86(6), 609-618 (2009).